Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 3
---
OPERATING AND FINANCIAL REVIEW AND PROSPECTS.

The following discussion
and analysis of our financial condition and results of operations should be read together with our audited consolidated financial statements
and the accompanying notes thereto appearing at the of this annual report. We have prepared our consolidated financial statements in this
annual report in British pounds sterling and in accordance with IFRS, a s issued by the International
Accounting Standards Board, which may differ in material respects from generally accepted accounting principles in other jurisdictions,
including generally accepted accounting principles in the United States. IFRS differs in some significant respects from
U. S. GAAP.

The following discussion
and analysis contains forward-looking statements. Statements that are not statements of historical fact, including expression of management’s
beliefs and expectations, may be forward-looking in nature and based on current plans, estimates, projections and beliefs. Forward-looking
statements are applicable only as of the date made, and we undertake no obligation to update any of them in light of new information or
future events. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results
or outcomes to differ materially from those expressed in any forward-looking statement. These factors include those identified under the
headings “ Risk Factors” and “ Cautionary Note Regarding Forward-Looking Statements.”

This section begins with an
overview of the principal factors and trends affecting our results of operations. The overview is followed by a discussion of the components
of our income statement and our critical accounting policies and estimates that we believe are important to understanding the assumptions
and judgments reflected in our reported financial results. We then present an analysis of our results of operations for the last two fiscal
years. We contain one reportable segment, referred to as Pipeline Research and Development.

Recent Developments